Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04–20 Article

Lieberman, FS, Tsien, C, Berkey, B et al. (2006). Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04–20 . JOURNAL OF CLINICAL ONCOLOGY, 24(18_suppl), 1510-1510. 10.1200/jco.2006.24.18_suppl.1510

cited authors

  • Lieberman, FS; Tsien, C; Berkey, B; Curran, W; Werner-Wasik, M; Smith, R; Grossheim, L; Hug, E; Mehta, M

authors

publication date

  • June 20, 2006

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Neurosciences
  • Orphan Drug
  • Patient Safety
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 1510

end page

  • 1510

volume

  • 24

issue

  • 18_suppl